Global mRNA Vaccine Market Size By Target Diseases, By Technology Platforms, By Development Stage, By Geographic Scope And Forecast

mRNA Vaccine Market Size And Forecast

mRNA Vaccine Market size was valued at USD 10.6 Billion in 2023 and is projected to reach USD 48.6 Billion by 2030, growing at a CAGR of 20.2% during the forecast period 2024-2030.

Global mRNA Vaccine Market Drivers

The market drivers for the MRNA Vaccine Market can be influenced by various factors. These may include

•  Emergence of revolutionary Vaccine TechnologiesmRNA vaccines are a revolutionary kind of vaccination that have a number of benefits, including flexibility, scalability, and quick development. The field of vaccination has undergone a revolution thanks to the development of mRNA vaccine technology, which has also fueled the market for mRNA vaccines.
• Pandemic Preparedness and ResponseIn order to tackle emerging infectious illnesses, effective and quickly deployable vaccinations are desperately needed, as the COVID-19 pandemic demonstrated. As mRNA vaccines, like those created to combat SARS-CoV-2, showed they could be used to solve public health catastrophes, demand and funding for the development and manufacturing of mRNA vaccines surged.
• High Safety and Efficacy ProfilesClinical investigations have shown that mRNA vaccines have high efficacy rates, frequently surpassing those of conventional vaccination platforms. Furthermore, large-scale vaccination efforts have shown positive safety profiles and typically good toleration of these vaccinations. The increasing acceptability and implementation of mRNA vaccines can be attributed to their greater efficacy and safety.
• Versatility and AdaptabilityThe quick generation and customisation of vaccinations against a wide range of pathogens, including bacteria, viruses, and even cancer cells, is made possible by the versatility and adaptability of mRNA vaccine technology. This adaptability facilitates quick reactions to newly discovered infectious diseases and the creation of vaccinations that are specifically suited to each patient, which propels market expansion.
• Research and Development (R&D) ExpendituresConsiderable funds are allocated towards the advancement of mRNA vaccine technology, with the aim of improving vaccination efficacy, stability, and delivery techniques. The market is expanded by government financing, commercial investments, and academic-industry alliances that spur innovation and accelerate the development of novel mRNA vaccines.
• Partnerships and CollaborationsPartnerships and collaborations among government agencies, biotechnology corporations, pharmaceutical companies, and research institutes promote innovation, hasten the development of vaccines, and increase production capacity. Strategic alliances make it easier to share resources, knowledge, and technological advancements, which propels the mRNA vaccine industry’s expansion and makes vaccines more widely available and accessible.
• Growing Need for Preventive HealthcareAs the value of immunization and preventive healthcare becomes more widely recognized, there is a rising need for vaccines that stop infectious diseases. As part of global vaccination efforts, mRNA vaccines offer a viable means of preventing disease, which is propelling their use and market expansion.

Global mRNA Vaccine Market Restraints

Several factors can act as restraints or challenges for the mRNA Vaccine Market. These may include

• The synthesis of mRNA and the formulation of lipid nanoparticles are two specialized manufacturing procedures that are necessary for the production of mRNA vaccines. These processes can be resource-intensive and complex. Another issue is scalability. Significant obstacles, such as limitations in the manufacturing capacity, shortages of raw materials, and supply chain bottlenecks, arise when production is scaled up to meet global demand.
• Requirements for Storage and DistributionFor long-term storage and transportation, mRNA vaccines normally need to be kept at extremely low temperatures, such as -70°C. It is logistically difficult to maintain the cold chain infrastructure, which includes storage facilities, refrigeration units, and transportation arrangements, especially in areas with poor infrastructure or harsh weather.
• Vaccine hesitation and Public PerceptionAlthough mRNA vaccines have shown to be safe and effective, vaccine hesitation and public perception concerns continue to pose serious obstacles to their widespread implementation. Public confidence and uptake of mRNA vaccines can be hampered by misinformation, skepticism of vaccine production methods, and worries about possible side effects or long-term safety hazards.
• Affordability and Equitable AccessObtaining, distributing, and distributing mRNA vaccines in a cost-effective manner are obstacles that must be overcome, especially in low- and middle-income nations. Inadequate funding, vaccine nationalism, and disparities in healthcare systems might make it difficult to address global vaccine equality and serve vulnerable populations.
• Regulatory and Approval ProceduresStrict assessment of safety, effectiveness, and manufacturing quality standards is part of the regulatory approval procedures for mRNA vaccines. Timelines for market entry and commercialization tactics may be impacted by delays in regulatory clearances, adherence to regulations in various jurisdictions, and changing regulatory rules.
• The effectiveness of mRNA vaccines may be impacted by the appearance of new virus types, which may call for continued study, development, and possibly even revisions to vaccination formulations. For vaccine manufacturers, there are scientific and practical problems in addressing vaccine escape variations and guaranteeing sustained protection against viral strains that are constantly mutating.
• Intellectual Property Rights and Technology TransferEfforts to increase vaccine manufacturing capacity worldwide through collaboration and technology transfer may be hampered by intellectual property rights pertaining to mRNA vaccine technologies, such as patents and private know-how. It is still difficult to strike a balance between the need for technology transfer and information exchange to improve vaccine access and intellectual property rights.
• Vaccine Resistance and Anti-Vaccination MovementsOne major obstacle to attaining extensive vaccination coverage is resistance to vaccination, which is driven by anti-vaccination movements, conspiracy theories, and disinformation operations. Targeted communication tactics, community involvement, and attempts to foster trust are necessary to overcome vaccination resistance and increase vaccine adoption.
• Adverse Events and Safety MonitoringPreserving public faith in mRNA vaccines requires the monitoring and management of adverse events that occur after immunization, including uncommon but severe side effects. To address safety concerns and reduce vaccine reluctance, strong pharmacovigilance procedures, post-marketing surveillance, and open disclosure of safety data are essential.
• Competition from Conventional VaccinesInactivated or protein subunit vaccines, among other conventional vaccinations, are still often administered to combat infectious diseases. Long-term market dynamics and mRNA vaccine acceptance may be impacted by competition from well-established vaccination platforms and ongoing development into other vaccine technologies.

Global mRNA Vaccine Market Segmentation Analysis

The Global mRNA Vaccine Market is Segmented on the basis of Target Diseases, Technology Platforms, Development Stage and Geography.

mRNA Vaccine Market, By Target Diseases

•  Infectious DiseasesmRNA vaccines targeting infectious diseases such as COVID-19, influenza, Zika virus, respiratory syncytial virus (RSV), and cytomegalovirus (CMV).
•  CancermRNA vaccines designed to prevent or treat various types of cancer, including melanoma, breast cancer, prostate cancer, and lung cancer.mRNA Vaccine Market, Technology Platforms
• Lipid Nanoparticle (LNP) Delivery SystemsmRNA vaccines utilizing lipid nanoparticle delivery systems for efficient intracellular delivery of mRNA to target cells.
• Self-Amplifying RNA (saRNA) TechnologyAdvanced mRNA vaccine technology that allows for self-replication of RNA within cells, leading to enhanced immune responses.
• Nucleoside-Modified mRNAmRNA vaccines incorporating nucleoside modifications to improve stability, translation efficiency, and immunogenicity.mRNA Vaccine Market, Development Stage
•  PreclinicalmRNA vaccine candidates in the preclinical stage of development, undergoing laboratory testing and animal studies to assess safety and efficacy.
•  Clinical TrialsmRNA vaccines undergoing clinical trials, categorized into Phase I, Phase II, and Phase III trials to evaluate safety, immunogenicity, and efficacy in human subjects.
•  Approved/CommercializedmRNA vaccines that have received regulatory approval or authorization for marketing and commercial distribution.

mRNA Vaccine Market, By Technology Platforms

•  Lipid Nanoparticle (LNP) Delivery SystemsmRNA vaccines utilizing lipid nanoparticle delivery systems for efficient intracellular delivery of mRNA to target cells.
• Self-Amplifying RNA (saRNA) TechnologyAdvanced mRNA vaccine technology that allows for self-replication of RNA within cells, leading to enhanced immune responses.
• Nucleoside-Modified mRNAmRNA vaccines incorporating nucleoside modifications to improve stability, translation efficiency, and immunogenicity.

mRNA Vaccine Market,  By Development Stage

• PreclinicalmRNA vaccine candidates in the preclinical stage of development, undergoing laboratory testing and animal studies to assess safety and efficacy.
• Clinical TrialsmRNA vaccines undergoing clinical trials, categorized into Phase I, Phase II, and Phase III trials to evaluate safety, immunogenicity, and efficacy in human subjects.
• Approved/CommercializedmRNA vaccines that have received regulatory approval or authorization for marketing and commercial distribution.

mRNA Vaccine Market, By Geography

• North AmericaMarket conditions and demand in the United States, Canada, and Mexico.
• EuropeAnalysis of the MRNA VACCINE MARKET in European countries.
• Asia-PacificFocusing on countries like China, India, Japan, South Korea, and others.
• Middle East and AfricaExamining market dynamics in the Middle East and African regions.
• Latin America Covering market trends and developments in countries across Latin America.

Key Players

• The major players in the MRNA Vaccine Market are
• Pfizer (partnered with BioNTech)
• Moderna
•  CureVac
•  Translate Bio (acquired by Sanofi)
• Arcturus Therapeutics
•  Merck
•  AstraZeneca
• GlaxoSmithKline (GSK)
•  Imperial College London
•  BioNTech (partnered with Pfizer)

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.